Multi-center, Randomized, Double-blinded Study of Teriflunomide® in Radiologically Isolated Syndrome (RIS) The TERIS Study
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2017
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- Acronyms TERIS
- 29 Nov 2017 Planned End Date changed from 6 Jul 2021 to 25 Sep 2021.
- 29 Nov 2017 Planned primary completion date changed from 6 Jul 2019 to 25 Sep 2019.
- 29 Nov 2017 Status changed from not yet recruiting to recruiting.